The chemical structure of prostaglandin X (prostacyclin).

PubWeight™: 3.63‹?› | Rank: Top 1%

🔗 View Article (PMID 12538)

Published in Prostaglandins on December 01, 1976

Authors

N Whittaker, S Bunting, J Salmon, S Moncada, J R Vane, R A Johnson, D R Morton, J H Kinner, R R Gorman, J C McGuire, F F Sun

Articles citing this

Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A 23187. J Clin Invest (1978) 4.35

Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci U S A (1977) 3.74

Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology. J Lipid Res (2009) 2.71

Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sci U S A (1979) 2.07

Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin. Br J Pharmacol (1982) 2.01

Comparison of the vasodepressor effects of prostacyclin and 6-oxo-prostaglandin F1alpha with those of prostaglandin E2 in rats and rabbits. Br J Pharmacol (1978) 1.85

Role of basic science in the development of new medicines: examples from the eicosanoid field. J Biol Chem (2012) 1.55

EDHF: spreading the influence of the endothelium. Br J Pharmacol (2011) 1.54

Cardiac and renal prostaglandin I2. Biosynthesis and biological effects in isolated perfused rabbit tissues. J Clin Invest (1978) 1.48

Selective binding site for [3H]prostacyclin on platelets. J Clin Invest (1979) 1.47

Arachidonate metabolism in vascular disorders. J Clin Invest (1983) 1.43

The vascular endothelium-pathobiologic significance. Am J Pathol (1978) 1.30

Prostaglandins, bioassay and inflammation. Br J Pharmacol (2006) 1.24

Sensitivity of fatty acid cyclooxygenase from human aorta to acetylation by aspirin. Proc Natl Acad Sci U S A (1978) 1.17

Responses of human and baboon arteries to prostaglandin endoperoxides and biologically generated and synthetic prostacyclin: their relevance to cerebral arterial spasm in man. Br J Clin Pharmacol (1979) 1.16

Alpha toxin from Clostridium perfringens induces proinflammatory changes in endothelial cells. J Clin Invest (1997) 1.16

Regulation of endothelial cell cyclic nucleotide metabolism by prostacyclin. J Clin Invest (1981) 1.12

Adventures in vascular biology: a tale of two mediators. Philos Trans R Soc Lond B Biol Sci (2006) 1.10

A nucleotide receptor in vascular endothelial cells is specifically activated by the fully ionized forms of ATP and UTP. Biochem J (1992) 1.10

Effects of nicotine on cardiac prostaglandin and platelet thromboxane synthesis. Br J Pharmacol (1978) 1.09

Serotonin receptor-mediated stimulation of bovine smooth muscle cell prostacyclin synthesis and its modulation by platelet-derived growth factor. Proc Natl Acad Sci U S A (1981) 1.06

Prostacyclin and thromboxane in diabetes. Br Med J (Clin Res Ed) (1981) 1.01

The binding of [3H]-prostacyclin to membranes of a neuronal somatic hybrid. Br J Pharmacol (1981) 1.00

Influence of prostaglandin analogues on epithelial cell proliferation and xenograft growth. Br J Cancer (1980) 0.99

Effects of indomethacin, piroxicam and selected prostanoids on gastric acid secretion by the rat isolated gastric mucosa. Br J Pharmacol (1985) 0.99

Prostacyclin (PGI2) inhibits the formation of platelet thrombi induced by adenosine diphosphate (ADP) in vivo [proceedings]. Br J Pharmacol (1977) 0.97

Stimulation of renin release by 6-oxo-prostaglandin E1 and prostacyclin. Br J Pharmacol (1982) 0.93

Twenty-four- and 48-hour canine liver preservation by simple hypothermia with prostacyclin. Ann Surg (1982) 0.93

Prostacyclin-dependent activation of adenylate cyclase in a neuronal somatic cell hybrid: prostanoid structure-activity relationships. Br J Pharmacol (1980) 0.92

2-Chlorohexadecanal and 2-chlorohexadecanoic acid induce COX-2 expression in human coronary artery endothelial cells. Lipids (2008) 0.91

(5Z)-carbacyclin discriminates between prostacyclin-receptors coupled to adenylate cyclase in vascular smooth muscle and platelets. Br J Pharmacol (1987) 0.91

Coronary vasoconstrictor and vasodilator actions of arachidonic acid in the isolated perfused heart of the rat. Br J Pharmacol (1982) 0.91

Unusual pulmonary vasodilator activity of 13,14-dehydroprostacyclin methyl ester: comparison with endoperoxides and other prostanoids. Proc Natl Acad Sci U S A (1977) 0.88

Increased levels of 6-oxo-PGF1 alpha in human skin following ultraviolet B irradiation. Br J Clin Pharmacol (1982) 0.88

Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations. Br J Pharmacol (2006) 0.87

Inhibition of human platelet thromboxane synthetase by 9,11-azoprosta-5,13-dienoic acid. Proc Natl Acad Sci U S A (1977) 0.87

Effects of prostaglandins E2 and I2 on human lymphocyte transformation in the presence and absence of inhibitors of prostaglandin biosynthesis. Br J Pharmacol (1979) 0.86

Learning how membrane fatty acids affect cardiovascular integrity. J Membr Biol (2005) 0.85

Models for investigating the aetiology of cerebral arterial spasm: comparative responses of the human basilar artery with rat colon, anococcygeus, stomach fundus, and aorta and guinea-pig ileum and colon. Br J Pharmacol (1978) 0.84

Actions of amiloride analogues on prostacyclin synthesis by rat aortic rings. Br J Pharmacol (1987) 0.84

Factors affecting prostacyclin formation by the rat pregnant myometrium. Br J Pharmacol (1980) 0.84

The prostanoids in hemostasis and thrombosis: a review. Am J Pathol (1980) 0.83

Time course change of COX2-PGI2/TXA2 following global cerebral ischemia reperfusion injury in rat hippocampus. Behav Brain Funct (2014) 0.82

Synthesis of 13,14-dehydroprostacyclin methyl ester: a potent inhibitor of platelet aggregation. Proc Natl Acad Sci U S A (1977) 0.82

Role of prostacyclin in pulmonary hypertension. Glob Cardiol Sci Pract (2014) 0.81

Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. Circ Res (2013) 0.81

Coronary vasodilator activity of 13,14-dehydroprostacyclin methyl ester: comparison with prostacyclin and other prostanoids. Proc Natl Acad Sci U S A (1978) 0.81

Activated endothelial cells elicit paracrine induction of epithelial chloride secretion. 6-Keto-PGF1alpha is an epithelial secretagogue. J Clin Invest (1998) 0.80

The cyclo-oxygenase-dependent regulation of rabbit vein contraction: evidence for a prostaglandin E2-mediated relaxation. Br J Pharmacol (1999) 0.80

Prostaglandins D and F with highly selective agonist actions [proceedings]. Br J Pharmacol (1977) 0.80

The arachidonic acid cascade. The prostaglandins, thromboxanes and leukotrienes. Inflammation (1984) 0.79

Prostaglandins and model aspects of thrombosis. Postgrad Med J (1977) 0.79

Prostacyclin (PGI2) inhibits the formation of platelet thrombi in arterioles and venules of the hamster cheek pouch. Br J Pharmacol (1978) 0.79

Nobel lecture. Adventures and excursions in bioassay--the stepping stones to prostacyclin. Postgrad Med J (1983) 0.79

PGI2 as a regulator of CD4+ subset differentiation and function. Prostaglandins Other Lipid Mediat (2011) 0.78

Prostacyclin (PGI2) inhibits the formation of platelet thrombi in arterioles and venules of the hamster cheek pouch. 1977. Br J Pharmacol (1997) 0.78

Nobel lecture, 8th December 1982. Adventures and excursions in bioassay: the stepping stones to prostacyclin. Br J Pharmacol (1983) 0.78

Thrombosis, platelets, microparticles and PAH: more than a clot. Drug Discov Today (2014) 0.78

Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension. Clin Med Insights Circ Respir Pulm Med (2012) 0.77

Potential therapeutic applications of aspirin and other cyclo-oxygenase inhibitors. Br J Clin Pharmacol (1980) 0.77

Transformation of arachidonate into 6-oxoprostaglandin F1 alpha, thromboxane B2 and prostaglandin E2 by sheep lung microsomal fraction. Biochem J (1978) 0.76

Catalytic asymmetric formal synthesis of beraprost. Beilstein J Org Chem (2015) 0.76

Quick change artist: endothelium-derived relaxing factor in resistance arteries. Hypertension (2011) 0.75

Vascular relaxing activity and stability studies of 10,10-difluoro-13,14-dehydroprostacyclin. Proc Natl Acad Sci U S A (1980) 0.75

The effect of prolonged treatment with sulphinpyrazone on thromboxane A2 and prostacyclin in man. Br J Clin Pharmacol (1982) 0.75

Benefit-Risk Assessment of Fish Oil in Preventing Cardiovascular Disease. Drug Saf (2016) 0.75

Effect of various doses of acetylsalicylic acid in combination with dipyridamole on the balance between prostacyclin and thromboxane in human serum. Br J Pharmacol (1981) 0.75

Trapped blood elements within the decidua of the rat pregnant uterus generate a lipoxygenase product(s) which inhibits myometrial prostacyclin synthesis. Br J Pharmacol (1981) 0.75

Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects. Br J Clin Pharmacol (2012) 0.75

Prostacyclin activity in rat kidney stimulated by angiotensin II. Br J Exp Pathol (1979) 0.75

Articles by these authors

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol (1971) 37.53

Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44

Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 18.41

Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature (1969) 13.60

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19

Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature (1986) 9.93

Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol (1990) 8.85

Prostaglandins: their disappearance from and release into the circulation. Nature (1967) 8.66

Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A (1989) 8.34

The release and fate of vaso-active hormones in the circulation. Br J Pharmacol (1969) 7.90

Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc Natl Acad Sci U S A (1989) 7.79

L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun (1988) 7.77

Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 7.69

Prostaglandins released by the spleen. Nature (1968) 7.61

Television viewing time and mortality: the Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Circulation (2010) 7.03

Nitric oxide synthases in mammals. Biochem J (1994) 6.50

A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol (1989) 6.30

Altered immune responses in mice lacking inducible nitric oxide synthase. Nature (1995) 6.20

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A (1999) 5.96

The enzymatic preparation of [alpha-32P]ATP, [alpha-32P]GTP, [32P]cAMP, and [32P]cGMP, and their use in the assay of adenylate and guanylate cyclases and cyclic nucleotide phosphodiesterases. Adv Cyclic Nucleotide Res (1979) 5.93

Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol (1990) 5.87

Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol (1971) 5.62

Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (1992) 5.36

Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol (1987) 5.23

A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun (1989) 5.14

The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol (1987) 4.88

Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A (1993) 4.82

Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A (1988) 4.77

Environmental determinants of physical activity and sedentary behavior. Exerc Sport Sci Rev (2000) 4.73

Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev (1978) 4.66

Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet (1987) 4.55

Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54

Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A (1990) 4.49

Inactivation of prostaglandins by the lungs. Nature (1970) 4.47

Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44

Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol (1986) 4.23

Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett (1994) 4.19

The enzymatic preparation of [alpha-(32)P]nucleoside triphosphates, cyclic [32P] AMP, and cyclic [32P] GMP. Biochim Biophys Acta (1979) 4.16

Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet (1977) 4.11

An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A (1990) 3.98

Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc Natl Acad Sci U S A (1992) 3.91

Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature (1990) 3.81

Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins (1977) 3.80

Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins (1977) 3.74

Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet (1978) 3.74

Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J (1989) 3.70

Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J Pharmacol Exp Ther (1990) 3.55

Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nat New Biol (1972) 3.54

Widespread tissue distribution, species distribution and changes in activity of Ca(2+)-dependent and Ca(2+)-independent nitric oxide synthases. FEBS Lett (1991) 3.43

Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature (1972) 3.30

Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med (1979) 3.29

Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A (1995) 3.28

Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res (1977) 3.28

The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun (1987) 3.25

Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med (1990) 3.20

Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature (1973) 3.20

Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res (1992) 3.15

Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun (1990) 3.14

Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest (1994) 3.11

Stimulation of human eosinophil and neutrophil polymorphonuclear leukocyte chemotaxis and random migration by 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid. J Clin Invest (1977) 3.10

Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci U S A (1998) 3.10

An improved method for washing of human platelets with prostacyclin. Thromb Res (1983) 3.07

Associations of TV viewing and physical activity with the metabolic syndrome in Australian adults. Diabetologia (2005) 3.02

A new approach to anti-inflammatory drugs. Biochem Pharmacol (1979) 2.95

Control of regional blood flow by endothelium-derived nitric oxide. Hypertension (1990) 2.93

Cutaneous disease and drug reactions in HIV infection. N Engl J Med (1993) 2.89

Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci U S A (1988) 2.84

Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83

Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. Nature (1991) 2.82

Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun (1991) 2.79

A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A (2001) 2.77

Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J Exp Med (1973) 2.75

Nitric oxide from L-arginine stimulates the soluble guanylate cyclase in adrenal glands. Biochem Biophys Res Commun (1989) 2.73

Nitric oxide synthase activities in human myocardium. Lancet (1993) 2.72

Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A (1994) 2.70

Nitric oxide synthesized from L-arginine regulates vascular tone in the coronary circulation of the rabbit. Br J Pharmacol (1989) 2.68

Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins (1977) 2.67

Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis (1992) 2.63

The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc Natl Acad Sci U S A (1990) 2.63

Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis (1989) 2.58

An analysis of physicians' reasons for prescribing long-term digitalis therapy in outpatients. J Chronic Dis (1985) 2.53

NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol (1989) 2.53